Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Holds Annual Meeting with Director Elections and Audit Approval
Summary
Apellis Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 5, 2024, where stockholders elected two new class I directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved an advisory vote on executive compensation. Paul Fonteyne and Stephanie Monaghan O'Brien were elected as directors with 98,837,712 and 80,481,023 votes respectively. Deloitte & Touche LLP was ratified as the independent auditor with 109,564,727 votes in favor, and the advisory vote on executive compensation received 93,573,357 votes in favor.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement